Keytruda scored an approval in lung cancer, but its narrow label will likely have it playing second fiddle.
Keytruda approved in non-small cell lung cancer; Enbrel biosimilar inches closer to approval; study finds no link between autism and vaccines
A GSK manager said that bringing digital devices to clinical trials could lower the cost of bringing medicines to patients.
By equipping patients with biosensors, wearable devices and mobile apps, clinical R&D teams have the opportunity to gain unprecedented insight about the patient experience.
The drugmaker's marketing teams will likely lean on its dosing profile to gain an edge in the crowded diabetes market.
An analysis of R&D data from 14 large drugmakers found that pharma is having renewed success in bringing medicines to market.
Oncologist says cancer drug prices defy markets; Jardiance slashes cardiovascular risk by one-third; Allergan wins approval for antipsychotic
The conference will offer a glimpse at new data testing possible treatment strategies for combination therapies in the first-line setting.
Novartis launches Zarxio, the first US biosimilar; UCB sells its generic business; one-third of children with ADHD are diagnosed before they turn six
Novartis and Amgen form neuroscience collaboration; the FDA approves a drug for people undergoing chemotherapy; a judge considers denying Pfizer's request to toss federal lawsuit
Amgen's Repatha will come to market priced $500 lower than the cost of Sanofi and Regeneron's Praluent.
Longtime ICC leader Viviano moves to the client side to help the start-up build its marketing team and become a commercial contender.
Eli Lilly's and BI's diabetes medication Jardiance becomes the first blood glucose-lowering drug to demonstrate it can reduce the risk of heart attack and stroke.
Sprout plans to hire 200 sales reps, targeting 30,000 doctors, to accompany the drug's launch.
A judge rules against Amgen in Neupogen case; FDA advisory panel recommends Breio Ellipta for adults with asthma; AstraZeneca partners with Daiichi Sankyo to sell Movantik
The Herpes zoster vaccine candidate showed relatively strong efficacy in a Phase-III trial, but its dosing is less convenient than an older product sold by rival Merck.
The drugmaker is poised to cut 14 pipeline projects loose.
Allergan's latest pipeline news was a mix of the good and the bad. The good: a potential Lucentis competitor is progressing. The bad: migraine medication Semprana has stalled.
Colorado's version of the FDA's compassionate use rule does not sit well with lobbying group Pharmaceutical Research and Manufacturers of America.
Sales of its big diabetes franchise rose 3% vs. the same period last year, while drops in Singulair and Nasonex revenue marked the quarter. The company is slated to reveal pipeline progress next week.
Roche also announced first-quarter sales shrank 1%.
Higher prices helped insulate Q4 and annual sales, which fell and rose 2%, respectively. Lilly said its insulin glargine biosimilar will go nowhere if it is not substantially different from the competition.
The company said it may use Phase II data of a breast cancer drug for FDA review, part of an earnings presentation that also included its perspective on what a pre-2017 breakup would take.
Our year-end list captures the 10 that sparked heaviest interest.
Goldman Sachs's Jami Rubin says AbbVie's pipeline assets make it a stealth competitor.
New results from its Phase II safety trial show the LDL-cholesterol lowerer was not associated with a major increase in adverse events vs. standard of care.
An analyst notes that early Phase III results in a psoriasis clinical trial could change the drug's efficacy profile. It could also fill out the financial potential of a standalone innovative unit, should Pfizer divide.
The drug maker says it is accelerating development of new drugs and focusing on expanding indications of current ones.
The drug maker is adding Amplimunne's cancer portfolio to subsidiary MedImmune's oncology efforts, one of several recent deals to add heft.
Analyst Seamus Fernandez writes that Merck needs to undergo a deep overhaul, continuing the summer narrative that has enveloped Pfizer and Novartis.
Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.